Physicochemical Properties
| Molecular Formula | C27H27NO5 |
| Molecular Weight | 445.51 |
| Exact Mass | 445.188 |
| CAS # | 1800576-41-3 |
| Appearance | Typically exists as solid at room temperature |
| Density | 1.3±0.1 g/cm3 |
| Boiling Point | 685.9±55.0 °C at 760 mmHg |
| Flash Point | 368.6±31.5 °C |
| Vapour Pressure | 0.0±2.2 mmHg at 25°C |
| Index of Refraction | 1.656 |
| LogP | 2.96 |
| SMILES | C1C=C(C(C2C=CC(C(C3=CC=C(OCC(O)CO)C=C3)=O)=CC=2)=CC=1C(=O)NC1CC1)C |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | NJK14047 (3-10 μM) inhibits the expression of inflammatory cytokines IL-1β, TNF-α, IL-6, IL-17A, RANKL and MMP-3 in human SW982 synovial cells stimulated by lipopolysaccharid (HY-D1056) [1]. NJK14047 (3-10 μM) dose-dependently inhibits the differentiation of naive CD4+T cells into Th1, Th2 and Th17 cells [1]. |
| ln Vivo | NJK14047 (2.5 mg/kg, intraperitoneal injection, 7-21 days) can improve collagen-induced rheumatoid arthritis (CIA) in the DBA-1J mouse model and imiquimod (HY-B0180)-induced psoriasis (IIP) in the BALB/c mouse model, inhibiting the expression of Th1, Th2, Th17 and Treg cytokines [1]. |
| Animal Protocol |
Animal/Disease Models:collage-induced rehumatoid arthritis in DBA-1J mice and imiquimod-induced psoriasis in BALB/c mice[1] Doses: 2.5 mg/kg Route of Administration: i.p. for 7 days for IIP-administrated BALB/c mice, i.p. for 21 days for CIA-administrated CBA-1J mice Experimental Results: Ameliorated the collage-induced arthritis and CIA caused cartilage damage, inflammation, pannus formation, bone corrosion, and synovial hyperplasia. Ameliorated the imiquimod induced psoriasis and IIP caused keratinocyte proliferation. |
| References |
[1]. NJK14047 inhibition of p38 MAPK ameliorates inflammatory immune diseases by suppressing T cell differentiation. Int Immunopharmacol. 2024 Mar 30;130:111800. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2446 mL | 11.2231 mL | 22.4462 mL | |
| 5 mM | 0.4489 mL | 2.2446 mL | 4.4892 mL | |
| 10 mM | 0.2245 mL | 1.1223 mL | 2.2446 mL |